Efficacy News and Research

RSS

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today provided a clinical update on its lead antibiotic candidate, eravacycline, and its Phase 3 global clinical program IGNITE (Investigating Gram-negative Infections Treated with Eravacycline).

21 Mar 2014

New treatment could halt progression of dementia

Researchers at the University of Texas Medical Branch at Galveston have discovered a way to potentially halt the progression of dementia caused by accumulation of a protein known as tau.

21 Mar 2014

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

20 Mar 2014

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces today positive final results for the first clinical trial on its innovative formulation combining insulin analog glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

20 Mar 2014

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.

20 Mar 2014

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.

20 Mar 2014

Novel method for evaluating treatment of obesity-related food behavior

Researchers at the University of Cambridge have developed a novel method for evaluating the treatment of obesity-related food behavior. In an effort to further scientific understanding of the underlying problem, they have published the first peer-reviewed video of their technique in JoVE, the Journal of Visualized Experiments.

20 Mar 2014

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.

From Zilico 19 Mar 2014

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris.

19 Mar 2014

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.

19 Mar 2014

Dartmouth, Aeras to jointly conduct trial of DAR-901 vaccine against TB

Dartmouth's Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world's deadliest diseases. The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of TB in a trial known as the DarDar Trial.

19 Mar 2014

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).

19 Mar 2014

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia.

19 Mar 2014

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology".

18 Mar 2014

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.

18 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.

18 Mar 2014

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.

17 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Efficacy News and Research

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

New treatment could halt progression of dementia

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

Adocia announces positive final results for first clinical trial of BioChaperone Combo

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Novel method for evaluating treatment of obesity-related food behavior

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Dartmouth, Aeras to jointly conduct trial of DAR-901 vaccine against TB

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News